Bruker Corporation · NASDAQ:BRKR

Bruker — BofA Securities 2021 Virtual Health Care Conference

14 slides from Bruker's conference presentation, May 11, 2021

  1. Slide 1: Bruker Corporation

    BANK OF AMERICA SECURITIES VIRTUAL HEALTH CARE CONFERENCE Bruker Corporation Nasdaq: BRKR Frank Laukien, PhD, President & CEO Mark Munch, PhD, President, Bruker Nano Group May 11, 2021

  2. Slide 2: Safe Harbor Statement

    BRUKER CORP ORATI ON Safe Harbor Statement Any statements contained in this presentation which do not describe historical facts may constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 193

  3. Slide 3: Q1 2021: Business and Market Recovery Lead to Significant Step Ups in Revenues, Margins and EPS

    Q1 2021 BUSINESS UP DATE Q1 2021: Business and Market Recovery Lead to Significant Step Ups in Revenues, Margins and EPS Q1 2021 Performance Year-over-Year Q1 Financials ❖ Revenues increase $130.7M, or +30.8% Revenues [$M] ▪ Organic growth of +23.8%, with BSI up +25.6% and BEST up +7.1% 554.7 +30.8%

  4. Slide 4: FY 2021 revenue growth, non-GAAP operating margin and non-GAAP EPS outlook

    F Y 2021 GUIDAN CE FY 2021 revenue growth, non-GAAP operating margin and non- GAAP EPS outlook FY 2021 Assumptions FY 2021 Non-GAAP (Comparison to prior Year-over-Year Guidance guidance in parentheses) ▪ Organic revenue growth: +11% to +13% Revenue Growth +14% to +16% (up from +7% to +9% prior guida

  5. Slide 5: Project Accelerate 2.0

    BRUKER 2021 AN D BEYON D Project Accelerate 2.0 Differentiated, High Value, Innovative Expanded Strategy & Incremental TAMs: ▪ Unbiased Proteomics & Multiomics: $5-6B TAM Life Science Research & Diagnostic ▪ Spatial Biology & Single-Cell Multiomics: $3-5B TAM Solutions ▪ Microbiology & Molecular Dx:

  6. Slide 6: Faster growth from six expanded high-growth, high-margin initiatives

    P ROJECT ACCELERATE 2 .0 Faster growth from six expanded high-growth, high-margin initiatives Unbiased 4D Proteomics & Consumables, Software, Unbiased 4D Multiomics, Functional Service & Aftermarket Proteomics & Structural Biology Consumables, assays, services, Multiomics MS and NMR solutions for li

  7. Slide 7: Canopy quantitative, high-resolution spatial biology & targeted single-cell multiomics research

    SP ATIAL BIOLOG Y & SIN G LE -CELL M ULTIOMICS Canopy quantitative, high-resolution spatial biology & targeted single-cell multiomics research true single-cell resolution Bruker ChipCytometry™: Quantitative Spatial Biology & Single-Cell Targeted Proteomics 8-log PD-1 expression in H&N tumor tissue d

  8. Slide 8: Vutara VXL Best-in-Class Super-Resolution Biological Workstation for Spatial Biology

    SP ATIAL BIOLOG Y & SIN G LE -CELL M ULTIOMICS Vutara™ VXL Best-in-Class Super-Resolution Biological Workstation for Spatial Biology Single Cell & Sub-Cellular Targeted Spatial Genomics, Transcriptomics and Proteomics ▪ Multiscale widefield & super-resolution imaging ▪ Leading-edge OligoSTORM, ORCA,

  9. Slide 9: Acuity Spatial Genomics For In Situ Spatial 3D Genomics

    SP ATIAL BIOLOG Y & SIN G LE -CELL M ULTIOMICS Acuity Spatial Genomics For In Situ Spatial 3D Genomics New venture, majority-owned by Bruker, opening a new frontier in spatial 3D genomics and multiomic analyses for discovery ▪ Leverages patented innovations developed in the lab of Ting Wu, PhD, Prof

  10. Slide 10: Appendix

    BANK OF AMERICA SECURITIES VIRTUAL HEALTH CARE CONFERENCE Appendix

  11. Slide 11: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

    BRUKER CORP ORATI ON Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) (1) Bruker Scientific Instruments (BSI) revenue reflects the sum of the BSI Life Science and BSI Nano Segments as presented in our 2020 Form 10-K. © 2021 Bruker BofA Securities Virtual Health Care Conference | May

  12. Slide 12: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

    BRUKER CORP ORATI ON Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) © 2021 Bruker BofA Securities Virtual Health Care Conference | May 11, 2021 | 12

  13. Slide 13: Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited)

    BRUKER CORP ORATI ON Reconciliation of GAAP to Non-GAAP Financial Measures (Unaudited) With respect to our outlook for 2021 non-GAAP operating margin, non-GAAP EPS and non-GAAP tax rate, we are not providing the most directly comparable GAAP financial measures or corresponding reconciliations to suc

  14. Slide 14: ;

    ;

Bruker — BofA Securities 2021 Virtual Health Care Conference on 6ix